Workflow
渤健上调2025年财务指引,阿尔茨海默病药物销量持续增长
BiogenBiogen(US:BIIB) Huan Qiu Wang·2025-08-01 07:10

Core Insights - Biogen has raised its financial guidance for 2025, driven by the continued growth in sales of its Alzheimer's drug, Leqembi, which has helped the company exceed Wall Street revenue expectations [1][3] Financial Performance - Biogen expects earnings per share for 2025 to reach $15.50 to $16.00, an increase from the previous forecast of $14.50 to $15.50 [3] - The company anticipates that total revenue for this year will remain flat compared to 2024, revising earlier expectations of a low single-digit percentage decline [3] - In Q2, Biogen reported total revenue of $2.6 billion, surpassing analyst expectations of $2.3 billion [3] Product Performance - Leqembi generated global revenue of $125 million in Q2, exceeding Wall Street expectations [3] - Sales of Leqembi in the previous two quarters were $96 million and $87 million, respectively [3] - The rare disease treatment Skyclarys achieved approximately $130 million in sales, aligning with expectations [3] Strategic Direction - Since taking office at the end of 2022, CEO Chris Viehbacher has focused on transforming Biogen by enhancing Leqembi sales, cutting costs, and reducing reliance on high-risk neurological drugs [3]